Subsequently, the impact of FXYD3 on ICC development was assessed by knocking down FXYD3 expression in mice through tail vein injection of adeno‐associated virus (AAV) shFXYD3 at 8 weeks (Figure 4E). Here, FXYD3 is linked to intrahepatic cholangiocarcinoma.